The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
In vitro functional analysis of HER2 variants in lung cancers to evaluate their oncogenic activity and predict clinical response to HER2 targeted therapies.
 
Michael Offin
No Relationships to Disclose
 
Zachary T. Olah
Employment - Bristol-Myers Squibb (I)
Stock and Other Ownership Interests - Bristol-Myers Squibb (I); Merck (I)
Research Funding - Bristol-Myers Squibb (I)
 
Joshua K. Sabari
No Relationships to Disclose
 
Nidhi Tandon
No Relationships to Disclose
 
Daniel Feldman
No Relationships to Disclose
 
Ghassan K. Abou-Alfa
Consulting or Advisory Role - Aduro Biotech (I); Agios; Array BioPharma (I); ASLAN Pharmaceuticals; Astellas Pharma; AstraZeneca; Bayer; Blueprint Medicines; Boston Scientific; Bristol-Myers Squibb (I); CASI Pharmaceuticals; Celgene; Celgene (I); Celsion; Delcath Systems; Eisai; EMD Serono (I); Gilead Sciences (I); Halozyme (I); IntegraGen; Ipsen; Janssen (I); Medimmune; Merck Serono; Merrimack; Merrimack (I); Momenta Pharmaceuticals (I); New B Innovation; Newlink Genetics (I); Onxeo; Opsona Therapeutics (I); Pfizer (I); Roche; Sanofi (I); SERVIER; Silenseed (I); Sillajen; Sirtex Medical; VAXIMM (I); Vicus Therapeutics; Vicus Therapeutics (I); Westhaven
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); CASI Pharmaceuticals (Inst); Chugai Pharma (Inst); Exelixis (Inst); Genentech (Inst); Incyte (Inst); MabVax (Inst); MedImmune (Inst); Momenta Pharmaceuticals (Inst); OncoMed (Inst); Polaris (Inst); Roche (Inst); Vicus Therapeutics (Inst)
Travel, Accommodations, Expenses - Polaris
 
Benjamin H. Lok
No Relationships to Disclose
 
Nitza Burck
Employment - NovellusDx
 
Gabi Tarcic
Employment - NovellusDx
Patents, Royalties, Other Intellectual Property - Patents submitted as a NovellusDx employee (Inst)
 
Ben Miron
Employment - NovellusDx
Leadership - NovellusDx
 
Maria E. Arcila
No Relationships to Disclose
 
Mark G. Kris
Consulting or Advisory Role - ARIAD; AstraZeneca; Genentech/Roche
Research Funding - Genentech/Roche (Inst); Puma Biotechnology (Inst)
 
Charles M. Rudin
Consulting or Advisory Role - Abbvie; AVEO; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; GlaxoSmithKline; Merck; Novartis
Research Funding - Biomarin
 
Bob T. Li
Consulting or Advisory Role - Biosceptre International; Roche; Thermo Fisher Scientific
Research Funding - AstraZeneca (Inst); BioMed Valley Discoveries (Inst); GRAIL (Inst); Illumina (Inst); Roche/Genentech (Inst)